Daqing Cai
Directeur/Membre du Conseil chez Beijing Shenogen Pharma Group Ltd.
Profil
Daqing Cai is currently a Director at Shenogen Pharma Group Ltd.
and Appia Bio, Inc. He previously worked as a Managing Director at Legend Capital Co. Ltd.
from 2015 to 2018, and as an Independent Director at Bionano Genomics, Inc. from 2014 to 2019.
He also served as a Director at Innovent Biologics, Inc., Indi Molecular, Inc., and Axonics, Inc. Additionally, he was the Chief Financial Officer & Director at Beijing Genomics Institute from 2014 to 2016.
Dr. Cai holds an MBA from Yale University, a doctorate from the University of California, Berkeley, and an undergraduate degree from the University of Science & Technology of China.
Postes actifs de Daqing Cai
| Sociétés | Poste | Début |
|---|---|---|
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Directeur/Membre du Conseil | - |
Appia Bio, Inc.
 Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Directeur/Membre du Conseil | - |
Anciens postes connus de Daqing Cai
| Sociétés | Poste | Fin |
|---|---|---|
| BIONANO GENOMICS, INC. | Directeur/Membre du Conseil | 21/08/2019 |
Legend Capital Co. Ltd.
 Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Corporate Officer/Principal | 01/04/2018 |
Beijing Genomics Institute
 Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Directeur Financier/CFO | 01/01/2016 |
Indi Molecular, Inc.
 Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Directeur/Membre du Conseil | - |
| INNOVENT BIOLOGICS, INC. | Directeur/Membre du Conseil | - |
Formation de Daqing Cai
| University of Science & Technology of China | Undergraduate Degree |
| Yale University | Masters Business Admin |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIONANO GENOMICS, INC. | Health Technology |
| AXONICS, INC. | Health Technology |
| INNOVENT BIOLOGICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Beijing Genomics Institute
Beijing Genomics Institute BiotechnologyHealth Technology Part of BGI Genomics Co., Ltd., Beijing Genomics Institute develops science and technology services in the genomics field. The company is based in Shenzhen, China. | Health Technology |
Legend Capital Co. Ltd.
Legend Capital Co. Ltd. Investment ManagersFinance Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China. | Finance |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | Health Technology |
Indi Molecular, Inc.
Indi Molecular, Inc. BiotechnologyHealth Technology Indi Molecular, Inc. is a life sciences company that develops a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. It offers products used by physicians and patients to manage complex and serious diseases like cancer, diabetes, and Alzheimer's. The company was founded by Michael Phelps, Albert A. Luderer, Leroy E. Hood, and Jim Heath in 2013 and is headquartered in Culver City, CA. | Health Technology |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | Health Technology |
